FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.